Cloning and production of human von Willebrand factor GPIB binding domain polypeptides and methods of using same
AssigneeBio-Technology General Corp.
InventorsLeonard Garfinkel, Tamar Richter
Life of this patent
Estimating the term…
Abstract
The subject invention provides non-glycosylated, biologically active polypeptides which comprise the vWF (von Willebrand Factor) GP1b binding domain. These polypeptides, may be used to inhibit platelet adhesion and aggregation in the treatment of subjects with conditions such as cerebrovascular disorders and cardiovascular disorders. This invention also provides expression plasmids encoding these polypeptides as well as methods of producing by transforming a bacterial cell and recovering such polypeptides. In addition, the subject invention provides methods of treating and preventing cerebrovascular, cardiovascular and other disorders using these polypeptides, to inhibit platelet aggregation.
Claims27
A biologically active composition comprising a polypeptide having the amino acid sequence ##STR7## wherein X is NH.sub.2 -methionine- or NH.sub.2 -;
- A is a sequence of at least 1, but no more than 5 amino acids, which sequence is present in naturally-occurring human vWF, the carboxy terminal amino acid of which is the tyrosine #508 shown in FIG. 12 and each succeeding amino acid of which is the next successive N-terminal amino acid shown in FIG. 12;
- B is a sequence of at least 1, but no more than 33 amino acids, which sequence is present in naturally-occurring human vWF, the amino terminal amino acid of which is the aspartic acid #696 shown in FIG. 12 and each succeeding amino acid of which is the next successive C-terminal amino acid shown in FIG. 12;
- and
- the two cysteines included in the sequence are joined by a disulfide bond.
Dependencies are inferred from the claim text.